Welcome to the e-CCO Library!

DOP049: Combination therapy of cyclosporine and vedolizumab is effective and safe for severe, steroid-resistant ulcerative colitis patients: A prospective study
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Tarabar1*, K. El Jurdi2, O. Yvellez2, Z. Milenkovic1, S. Petrovic1, B. Subotic1, T.P. Brocic1, I. Brcerevic1, O. Latinovic3, D.T. Rubin2

Created: Thursday, 21 February 2019, 9:14 AM
DOP049: Efficacy and safety of golimumab induction 
for moderate-to-severe ulcerative colitis in 
the United Kingdom: results from the 
GO-COLITIS study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

C. Probert*1, D. R. Gaya2, P. J. Hamlin3, P. Irving4, S. Sebastian5, G. Gillespie6, H. Tate6, C. Wheeler6

Created: Friday, 22 February 2019, 9:49 AM
DOP049: Inflammatory dyskinesis: defects of NF-κB dynamic behaviour as a new potential biomarker for personalized medicine in inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sellge G.*1, Papoutsopoulou S.2, Verdier J.1, Trautwein C.1, Bergey F.3, Burkitt M.4, Burkitt M.4, Sheibani R.5, Pierik M.6, Jonkers D.6, White M.2, Paszek P.2, Martins dos Santos V.3, Rosenstiel P.5, Müller W.2, Probert C.4 SysmedIBD Consortium2

Created: Wednesday, 20 February 2019, 10:36 AM
DOP04: Inflammatory Bowel Disease (IBD) and Solid Organ Transplantation. Natural history of pre-existing and de novo IBD patients. (EITOS study of GETECCU)
Year: 2022
Source: ECCO'22
Authors: Bastón Rey, I.(1);Calvino Suárez, C.(1);Luque, A.M.(2);Caballol, B.(3);Soutullo, C.(4);Bravo, A.(5);Castaño, A.(6);Gros, B.(7);Bernal, L.(8);Diz Lois, M.T.(9);Alonso Galán, H.(10);Cañete, F.(11);Castro, B.(12);Pérez Galindo, P.(13);González Muñoza, C.(14);El Hajra, I.(15);Martínez Montiel , P.(16);Alonso Abreu, I.(17);Mesonero, F.(18);González Vivo, M.(19);Peries, L.(20);Martín Arranz, E.(21);Abril, C.(22);Marín Jiménez, I.(23);Baltar, R.(24);Vicuna, M.(25);Moreno, N.(26);Brunet, E.(27);Rubín de Célix, C.(28);Fajardo, I.(29);Cruz, N.(30);Rojas Feria, M.(2);Fernández Clotet, A.(3);Gimeno, M.(4);Zabana, Y.(31);Suárez Ferrer, C.(21);Rodríguez Lago, I.(32);Barreiro de Acosta, M.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP04: Single cell RNA sequencing identifies distinct intestinal inflammation patterns between primary sclerosing cholangitis-associated colitis and Ulcerative Colitis
Year: 2021
Source: ECCO'21 Virtual
Authors: Uniken Venema, W.(1);Bangma, A.(1);Van der Wijst, M.(2);Kats-Ugurlu, G.(1);Bjork, J.(1);Vich Vila, A.(1);Weersma, R.(1);Festen, E.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP04: Single cell RNA sequencing reveals a potential role for IFNγ in priming circulating monocytes for intestinal inflammatory function in Crohn's Disease.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Hornsby, E.(1)*;Gadhok, R.(1);Yadon, A.N.(2);Lindsay, J.O.(1);Stagg, A.J.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP04: The ability of epithelial regeneration is reduced in the Crohn’s disease patient-derived organoids, especially in TNF-α enriched condition
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. H. Song1, S. N. Hong*1, G. Seong1, T. J. Kim1, E. R. Kim1, D. K. Chang1, Y-H. Kim1, C. Lee1, C. Lee1

Created: Friday, 22 February 2019, 9:41 AM
DOP05 Perioperative Dietary Therapy in inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Adamina1, K. Gerasimidis2, R. Sigall-Boneh3,4, O. Zmora5, A. de Buck van Overstraeten6,7, M. Campmans-Kuijpers8, P. Ellul9, K. Katsanos10, P. Kotze11, N. Noor12, J. Schäfli-Thurnherr13, S. Vavricka13, C. Wall14, N. Wierdsma15, N. Yassin16, M. Lomer17, ECCO Topical Review on Perioperative Dietary Therapy in Inflammatory Bowel Disease

Created: Thursday, 30 January 2020, 10:12 AM
DOP050: Influence of disease location on vedolizumab efficacy in inflammatory bowel disease: a real-life multicentre experience
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Pestour1*, S. Nancey2, A.L. Charlois2, B. Bonaz1, B. Flourie2, G. Boschetti2, N. Mathieu1

Created: Thursday, 21 February 2019, 9:14 AM
DOP050: Serum proteomic analysis defines novel circulating inflammatory markers for Crohn's disease and response to anti-TNF therapy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Korf H.*1,2, Sabino J.1, Ballet V.3, de Bruyn M.1,4, Van Assche G.3, Ferrante M.3, Vermeire S.3

Created: Wednesday, 20 February 2019, 10:36 AM
DOP050: The efficacy of vedolizumab by disease activity and prior tumour necrosis factor-alpha antagonist failure in patients with ulcerative colitis or Crohns disease: post-hoc analyses from the GEMINI 1 and GEMINI 2 studies
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

G. D’Haens1, J.-F. Colombel*2, M. Dubinsky2, B. Abhyankar3, A. James3, K. Lasch4

Created: Friday, 22 February 2019, 9:49 AM
DOP051: Response and remission rates with up to 3 years of vedolizumab treatment in patients with ulcerative colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

E.V. Loftus Jr1, J.-F. Colombel*2, A. Previtali3, M. Smyth3

Created: Friday, 22 February 2019, 9:49 AM
DOP051: Serological biomarkers of tissue turnover can early identify responders to infliximab in Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

van Haaften W.T.*1,2, Mortensen J.H.3, Olesen M.L.3,4, Karsdal M.A.3, Olinga P.2, Bay-Jensen A.-C.3, Dijkstra G.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP051: Shorter disease duration is associated with higher response rates to vedolizumab in Crohn’s disease but not ulcerative colitis: a multi-centre consortium analysis
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Faleck1, A. Winters1, S. Chablaney1, P. Shashi2, J. Meserve3, A. Weiss4, S. Aniwan5, J.L. Koliani-Pace6, G. Kochhar2, B. Boland3, S. Singh3, R. Hirten1, E. Shmidt1, K. Lasch7, M. Luo7, M. Bohm8, S. V Sagi8, M. Fischer8, D. Hudesman9, S. Chang9, D. Lukin4, K. Sultan10, A. Swaminath11, N. Gupta12, C.A. Siegel6, B. Shen2, W.J. Sandborn3, S. Kane5, E.V. Loftus5, B.E. Sands1, J.-F. Colombel1, P.S. Dulai3*, R. Ungaro1

Created: Thursday, 21 February 2019, 9:14 AM
DOP052: Molecular response to ustekinumab in moderate-to-severe Crohn's disease by serum protein and biopsy gene expression analysis: results from Ustekinumab phase 3 studies
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Li K., Hayden K., Wadman E., Bhagat S., Emrich S., Jacobstein D., Gasink C., Brodmerkel C.

Created: Wednesday, 20 February 2019, 10:36 AM
DOP052: Ozanimod induces histological response and remission: results from the TOUCHSTONE study, a randomised, double-blind, placebo-controlled trial of ozanimod, an oral S1P receptor modulator, in moderate-to-severe ulcerative colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

W. Sandborn*1, B. Feagan2, G. D’Haens3, B. Levesque4, R. Pai5, S. Hanauer6, D. Wolf7, S. Vermeire8, S. Ghosh9, H. Smith10, M. Cravets10, P. Frohna10, S. Gujrathi10, R. Aranda10, A. Olson10

Created: Friday, 22 February 2019, 9:49 AM
DOP052: Vedolizumab vs. ustekinumab for Crohn’s disease: comparative effectiveness in a real-life observational cohort study (ICC case series)
Year: 2018
Source: ECCO '18 Vienna
Authors:

V. Biemans1,2*, C. van der Woude3, A. van der Meulen - de Jong4, G. Dijkstra5, N. de Boer6, B. Oldenburg7, C. Ponsioen8, A. de Vries3, D. Wintjens2, F. Hoentjen9, M. Pierik2, Dutch Initiative on Crohn and Colitis (ICC)

Created: Thursday, 21 February 2019, 9:14 AM
DOP053: Effects of oral tofacitinib on patient-reported outcomes in patients with moderate-to-severe Crohns disease: results of 2 Phase 2b randomised placebo-controlled trials
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

J. Panés*1, M. Moscariello2, E. Maller2, G. Chan2, W. Wang2, P. Healey3

Created: Friday, 22 February 2019, 9:49 AM
DOP053: Impact of concomitant immunomodulator use on vedolizumab effectiveness: a multicentre consortium propensity score-matched analysis
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Hudesman1, S. Chang1, P. Shashi2, A. Winters3, S. Chablaney3, J. Meserve4, A. Weiss5, S. Aniwan6, D. Faleck3, J.L. Koliani-Pace7, G. Kochhar2, B. Boland4, S. Singh4, R. Hirten3, E. Shmidt3, K. Lasch8, M. Luo8, M. Bohm9, S. V Sagi9, M. Fischer9, D. Lukin5, K. Sultan10, A. Swaminath11, N. Gupta12, C.A. Siegel7, B. Shen2, S. Kane6, E.V. Loftus6, B.E. Sands3, W.J. Sandborn4, J.-F. Colombel3, P.S. Dulai4*

Created: Thursday, 21 February 2019, 9:14 AM
DOP053: The fecal microbiome as a tool for monitoring and predicting response outcomes in ustekinumab-treated, anti-TNFα refractory Crohn's disease patients: results from the CERTIFI study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Doherty M.K.*1, Koumpouras C.1, Telesco S.E.2, Monast C.2, Brodmerkel C.2, Schloss P.D.1

Created: Wednesday, 20 February 2019, 10:36 AM